<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918408</url>
  </required_header>
  <id_info>
    <org_study_id>1005312</org_study_id>
    <nct_id>NCT03918408</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions</brief_title>
  <official_title>Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacific Clear Vision Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacific Clear Vision Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the Peschke PXL-330 system is safe and effective in the treatment of
      corneal thinning conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive keratoconus, pellucid marginal degeneration, infectious keratitis,
      or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on
      corneal crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy
      delivery. Patients will undergo monitoring for 1 year, with serial measurements of corneal
      topography, visual acuity, intraocular pressure, and visual function questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2029</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatment of patients with disease</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Randomized at outset</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean keratometry in diopters</measure>
    <time_frame>1 year</time_frame>
    <description>Average keratometry across the anterior topography of the cornea computed by a validated Scheimpflug topographer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of best corrected visual acuity on the validated early-treatment diabetic retinopathy study scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Keratoconus, Unstable</condition>
  <condition>Bacterial Keratitis</condition>
  <condition>Ectasia of Cornea</condition>
  <arm_group>
    <arm_group_label>Pulsed, accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mW, 5 sec, 5 sec off, 10 minutes of illumination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9 mW, continuous 10 minutes of illumination</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution</intervention_name>
    <description>Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea</description>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_label>Pulsed, accelerated</arm_group_label>
    <other_name>Corneal crosslinking</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Criterion 1,2,3 are required for all participants. Participants must
        also meet one or more of criteria 4-12 . Criterion 13 is relevant only for contact lens
        wearers

          1. 12 years of age or older

          2. Signed written informed consent

          3. Willingness and ability to comply with schedule for follow-up visits

          4. Presence of central or inferior steepening.

          5. Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid
             marginal degeneration

          6. Presence of one or more findings associated with keratoconus or pellucid marginal
             degeneration, such as:

               1. Fleischer ring

               2. Vogt's striae

               3. Decentered corneal apex

               4. Munson's sign

               5. Rizzutti's sign

               6. Apical Corneal scarring consistent with Bowman's breaks

               7. Scissoring of the retinoscopic reflex

               8. Crab-claw appearance on topography

          7. Steepest keratometry (Kmax) value â‰¥ 47.20 D

          8. I-S keratometry difference &gt; 1.5 D on the Pentacam/Galilei/Orbscan/Cassini map or
             topography map

          9. Posterior corneal elevation &gt;16 microns

         10. Thinnest corneal point &lt;485 microns

         11. Predicted Post LASIK/PRK stromal ablation depth &lt;350 microns or expected keratometry
             &gt;47.2 D, or patients undergoing PRK/SMILE in keratoconus suspect eyes

         12. Bacterial or fungal corneal keratitis persistent and not responding despite &gt; 2 weeks
             of standard antimicrobial therapy or with rapid progression of corneal thinning, with
             loss of &gt;25% corneal thickness

         13. Contact Lens Wearers Only:

               1. Removal of contact lenses for the required period of time prior to the screening
                  refraction:

        Contact Lens Type Minimum Discontinuation Time Soft 1 Week Soft Extended Wear 2 Weeks Soft
        Toric 3 Weeks Rigid gas permeable 2 Weeks per decade of wear

        Exclusion Criteria (any of the following are reasons for exclusion):

          1. Eyes classified as either normal or atypical normal on the severity grading scheme.

          2. Corneal pachymetry at the screening exam that is &lt;300 microns at the thinnest point in
             the eye(s) to be treated.

          3. Previous ocular condition (other than refractive error) in the eye(s) to be treated
             that may predispose the eye for future complications, for example:

               1. History of or active corneal disease (e.g., herpes simplex, herpes zoster
                  keratitis, recurrent erosion syndrome, acanthomeoeba, etc.)

               2. Clinically significant corneal scarring in the CXL treatment zone that is not
                  related to keratoconus or, in the investigator's opinion, will interfere with the
                  cross-linking procedure.

          4. Pregnancy (including plan to become pregnant) or lactation during the course of the
             study

          5. A known sensitivity to study medications

          6. Patients with nystagmus or any other condition that would prevent a steady gaze during
             the CXL treatment or other diagnostic tests.

          7. Patients with a current condition that, in the physician's opinion, would interfere
             with or prolong epithelial healing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BALAMURALI AMBATI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PCVI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BALAMURALI AMBATI, MD, PhD</last_name>
    <phone>541-343-5000</phone>
    <email>bambati@pcvi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Cherne, MD</last_name>
    <phone>541-343-5000</phone>
    <email>scherne@pcvi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pacific Clear Vision Institute</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BALAMURALI AMBATI, MD</last_name>
      <phone>706-231-3958</phone>
      <email>bambati@pcvi.com</email>
    </contact>
    <contact_backup>
      <last_name>Scott K Cherne, MD</last_name>
      <phone>5413435000</phone>
      <email>scherne@pcvi.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 14, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will be help in a secure location. While summary outcomes data will be provided on request to other researchers and periodically at scientific conferences, protected health information will not.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03918408/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

